Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
09 Janeiro 2024 - 10:05AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, said today that Chief Executive Officer
Yvonne Greenstreet has been selected as the 2024 Woman of the Year
by the Healthcare Businesswomen’s Association (HBA). The
announcement was made last evening at the J.P. Morgan Healthcare
Conference in San Francisco. Yvonne will be recognized at HBA’s
34th annual Woman of the Year event on May 10 in New York City.
The HBA Woman of the Year award honors an executive leader who
has made extraordinary contributions to healthcare and the
advancement of women in the workplace.
“During her three decades of leadership in the biopharmaceutical
industry, Yvonne has made an enormous impact through her work to
enable the development and delivery of medicines that have improved
the lives of people around the world,” said Mary Stutts, CEO of
HBA. “Yvonne is an inspirational and purpose-driven leader with a
passion for advancing health equity globally and a deep commitment
to building an inclusive, equitable, and supportive workplace
culture where women—and all employees—can thrive personally and
professionally.”
Yvonne joined Alnylam in 2016 as Chief Operating Officer, was
promoted to President and COO in 2020, and was appointed a Director
in late 2021 and Chief Executive Officer in January 2022. Under her
leadership, Alnylam has continued to drive the RNAi revolution that
is changing medicine, while consistently earning recognition as a
socially responsible company and exceptional workplace globally.
Alnylam has been named among Fortune’s Best Workplaces for Women,
included on the Bloomberg Gender Equality Index, and ranked as a
Best Workplace for Parents. Alnylam has also won recognition
multiple years in a row as a top employer by Science Magazine and
the Boston Globe, been named a Great Place to Work in many regions
outside the U.S., and earned inclusion in Newsweek’s list of
America’s Most Responsible Companies.
“Yvonne demonstrates leadership from the front,” said David
Pyott, retired chairman and CEO of Allergan and a member of
Alnylam’s board of directors. “She develops, mentors, and supports
colleagues at all levels. She is a kind and caring person who is a
great listener. She creates an environment where dedication to the
patient is first and foremost. Yvonne is well-recognized by other
industry and healthcare leaders for her rare combination of
personal charisma, scientific acumen, and business savvy.”
“Yvonne is a natural leader and mentor,” said Freda Lewis-Hall,
M.D., former Chief Medical Officer at Pfizer and a previous HBA
Woman of the Year. “Her brilliance, immeasurable aptitude to
envision the future of our industry, intrinsic leadership skills,
and compassion for patients and teammates has never ceased to amaze
me. As a successful woman in a male-dominated industry, she has
capably served as an inspiration to underrepresented groups and has
guided and supported the growth of so many people.”
Prior to joining Alnylam, Yvonne was Senior Vice President and
Head of Medicines Development at Pfizer serving on the executive
team leading a rapidly growing $16 billion division. Prior to
Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was
Senior Vice President and Chief of Strategy for Research and
Development. Yvonne had previously been in various positions of
increasing responsibility at GSK, including Senior Vice President
for Medicines Development and Chief Medical Officer for Europe.
Yvonne trained as a physician and earned her medical degree
(MBChB) from The University of Leeds in the UK. She also holds an
MBA from INSEAD Business school in France. She serves on the board
of directors of The American Funds. Additionally, she is a member
of the Scientific Advisory Committee of the Bill and Melinda Gates
Foundation, a member of the Discovery Council of Harvard Medical
School, and a member of Biotechnology Industry Organization (BIO)
Health Section Governing Board (HSGB).
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation
of RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and prevalent diseases with unmet need. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach yielding transformative
medicines. Since its founding in 2002, Alnylam has led the RNAi
Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), AMVUTTRA®
(vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and
Leqvio® (inclisiran), which is being developed and commercialized
by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn,
Facebook on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240109327860/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024